Accueil>>Analytical Standards>>Sphingosine-d7 (d18:1)

Sphingosine-d7 (d18:1) (Synonyms: (-)-Sphingosine-d7, D-erythro-Sphingosine C-18-d7)

Catalog No.GC40104

La sphingosine-d7 (d18:1) (érythrosphingosine-d7) est la D-érythro-sphingosine marquée au deutérium. La D-érythro-sphingosine (érythrosphingosine) est un activateur très puissant de la p32-kinase avec une EC50 de 8 μ ; M, et inhibe la protéine kinase C (PKC). La D-érythro-Sphingosine (Erythrosphingosine) est également un activateur de la PP2A.

Products are for research use only. Not for human use. We do not sell to patients.

Sphingosine-d7 (d18:1) Chemical Structure

Cas No.: 1246304-34-6

Taille Prix Stock Qté
500μg
170,00 $US
En stock
1mg
321,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sphingosine-d7 (d18:1) is intended for use as an internal standard for the quantification of sphingosine (d18:1) by GC- or LC-MS. Sphingosine (d18:1) is formed primarily from the breakdown of ceramide. Sphingosine (d18:1) inhibits protein kinase C and phosphatidic acid phosphohydrolase, whereas it activates phospholipase D and diacylglycerol (DAG) kinase. Phosphorylation of sphingosine (d18:1) by sphingosine kinases 1 and 2 (SPHK1, SPHK2) produces sphingosine-1-phosphate, a potent bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis.

Avis

Review for Sphingosine-d7 (d18:1)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sphingosine-d7 (d18:1)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.